Blog

Responses to CAR T-cell therapy deepen over time for lymphoma – Healio

Responses to CAR T-cell therapy deepen over time for lymphoma
Healio
Earlier results from ZUMA-1 showed axicabtagene ciloleucel (Yescarta; Kite Pharma, Gilead) — an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy — induced significant clinical benefit with a manageable safety profile for patients with

2018-06-05 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.